Jazz Pharmaceuticals plc

NasdaqGS:JAZZ 株式レポート

時価総額：US$16.0b

Jazz Pharmaceuticals 配当と自社株買い

配当金 基準チェック /06

Jazz Pharmaceuticals配当金を支払った記録がありません。

主要情報

n/a

配当利回り

-0.1%

バイバック利回り

総株主利回り-0.1%
将来の配当利回り0%
配当成長n/a
次回配当支払日n/a
配当落ち日n/a
一株当たり配当金n/a
配当性向n/a

最近の配当と自社株買いの更新

更新なし

Recent updates

ナラティブ更新 • Sep 03

JAZZ: First-Line HER2 GEA Success Will Anchor Future Oncology Leadership

Analysts have nudged their implied fair value estimate for Jazz Pharmaceuticals to $289.45 from $281.35, reflecting updated expectations for Ziihera following recent FDA approvals and new Street research that frames its potential peak sales range at $3 billion to $5 billion. Analyst Commentary Street commentary around Jazz Pharmaceuticals has turned more constructive following the recent FDA approvals for Ziihera and the updated peak sales range of US$3b to US$5b.
ナラティブ更新 • Aug 15

JAZZ: HER2 GEA Approval And Rare Epilepsy Deal Will Reshape Oncology Leadership

Analysts have lifted their fair value estimate for Jazz Pharmaceuticals from $257.00 to $281.35, citing higher modeled revenue growth, stronger profit margins, and a richer future P/E assumption that reflect recent price target increases across the Street and confidence in the company's expanding oncology and rare-epilepsy portfolio. Analyst Commentary Street research on Jazz Pharmaceuticals has been active, with a cluster of higher price targets and fresh coverage reflecting updated views on execution, growth mix, and risk around key franchises and pipeline assets.
Seeking Alpha • Aug 12

Jazz Pharmaceuticals Bolsters Epilepsy Division With Actio Biosciences Buyout

Summary Jazz Pharmaceuticals acquires Actio Biosciences for $820 million upfront, targeting rare KCNT1+ epilepsy with ABS-1230, a registrational-stage precision therapy. JAZZ delivered record Q2 2026 revenues of ~$1.2 billion, with strong year-on-year growth in key assets like Xywav (+13%) and Zepzelca (+42%). Despite a competitive narcolepsy landscape and $4.4 billion in debt, JAZZ's diversified portfolio, robust cash position, and M&A track record support a Buy rating. ABS-1230, with multiple FDA designations, could add $200–$400 million in peak sales if approved, I estimate, further strengthening JAZZ's epilepsy franchise. Read the full article on Seeking Alpha
ナラティブ更新 • Aug 01

JAZZ: Ziihera Launch Expectations Will Drive Future Multiple Compression Risk

The analyst price target for Jazz Pharmaceuticals has moved higher, with the fair value estimate shifting from $205.58 to $212.63. This change is supported by analysts citing a greater focus on higher-value oncology products, updated views on Ziihera and other oncology launches, and ongoing management of sleep-franchise risks.
ナラティブ更新 • Jul 18

JAZZ: Oncology Launch Execution Will Drive Future Multiple Compression Risk

Analysts have lifted the fair value estimate for Jazz Pharmaceuticals slightly, from about $200.51 to $205.58. This change reflects updated assumptions around a shifting product mix toward oncology and a series of higher Street price targets tied to upcoming launches and sleep-franchise risk management.
ナラティブ更新 • Jun 23

JAZZ: HER2 GEA Priority Review Will Support Future Oncology Leadership Narrative

Analysts have lifted the central analyst price target for Jazz Pharmaceuticals stock from $225.53 to $257.00, pointing to stronger conviction in Ziihera's potential uptake in gastroesophageal adenocarcinoma and biliary tract cancer, a firmer outlook for the oncology portfolio, and perceived resilience of the Xywav franchise. Analyst Commentary Recent research on Jazz Pharmaceuticals highlights a clear split between bullish analysts focused on Ziihera driven growth and oncology expansion, and more cautious voices focused on neurology concentration risk and competitive pressure.
分析記事 • Jun 18

Jazz Pharmaceuticals (JAZZ) Stock Could Be 73% Below Fair Value After Recent Pullback

Jazz Pharmaceuticals stock reaction puts recent performance in focus With no single headline event driving Jazz Pharmaceuticals (JAZZ) today, the stock’s recent performance and fundamentals take center stage, inviting investors to reassess how its current pricing lines up with reported results. See our latest analysis for Jazz Pharmaceuticals. At a share price of $226.93, Jazz Pharmaceuticals has recently given back some of its shorter term gains, with a 7 day share price return that declined...
ナラティブ更新 • Jun 06

JAZZ: Oncology Readouts And CNS Durability Will Support Future Upside Potential

Analysts have lifted their fair value estimate for Jazz Pharmaceuticals to $304.19 from $263.59, citing higher modeled revenue growth, stronger profit margins supported by views on Ziihera and zanidatamab, and confidence in Xywav patent protections that they argue could justify a modestly lower future P/E multiple. Analyst Commentary Recent Street research on Jazz Pharmaceuticals presents a mixed but generally constructive tone, with several bullish analysts pointing to patent clarity on Xywav and the commercial opportunity for Ziihera and zanidatamab as key support pillars for their models.
ナラティブ更新 • May 23

JAZZ: Oncology Execution Risks Will Drive Future Multiple Compression Concerns

Analysts have lifted the fair value estimate for Jazz Pharmaceuticals from $188.00 to about $200.51, citing a higher assumed future P/E multiple. They link this to growing confidence in the broader Ziihera and zanidatamab opportunities, even as they factor in slightly lower long term profit margins and ongoing competitive pressure on legacy neurology drugs.
分析記事 • May 13

We Think You Can Look Beyond Jazz Pharmaceuticals' (NASDAQ:JAZZ) Lackluster Earnings

The market was pleased with the recent earnings report from Jazz Pharmaceuticals plc ( NASDAQ:JAZZ ), despite the...
分析記事 • May 08

Jazz Pharmaceuticals plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Jazz Pharmaceuticals plc ( NASDAQ:JAZZ ) investors will be delighted, with the company turning in some strong numbers...
ナラティブ更新 • Apr 28

JAZZ: HER2 GEA Data Will Support Future Oncology Leadership Thesis

Analysts have nudged the price target on Jazz Pharmaceuticals higher to about $226, reflecting updated views on margins, central nervous system revenue durability, and upcoming oncology contributions following recent Q4 results and refreshed models. Analyst Commentary Recent Street research on Jazz Pharmaceuticals has centered on refreshed models following Q4 results, updated revenue guidance, and the expected contribution from oncology assets alongside the core central nervous system portfolio.
ナラティブ更新 • Apr 13

JAZZ: CNS Cash Flows And Upcoming Oncology Launches Will Shape Execution Risks

Analysts have increased their average price target on Jazz Pharmaceuticals by $13 to $255, citing more supportive assumptions around revenue growth, profit margins and a slightly lower future P/E following the recent Q4 results and updated guidance. Analyst Commentary Recent research on Jazz Pharmaceuticals has largely centered on updated price targets and ratings following the company’s Q4 report and new guidance.
ナラティブ更新 • Mar 30

JAZZ: CNS Cash Flows And HER2 Franchise Will Shape Oncology Execution Risks

Narrative Update on Jazz Pharmaceuticals Analysts have lifted price targets on Jazz Pharmaceuticals by roughly $10 to $45 into a $224 to $275 range, citing steady central nervous system demand, updated Ziihera and zanidatamab expectations following HERIZON-GEA data, and recent Q4 results that aligned with or modestly exceeded prior forecasts. Analyst Commentary Recent research on Jazz Pharmaceuticals has been broadly constructive, with several firms adjusting price targets higher after Q4 results and the HERIZON GEA data updates.
ナラティブ更新 • Mar 16

JAZZ: HER2 Data And CNS Cash Flows Will Balance Oncology Execution Risks

The analyst price target for Jazz Pharmaceuticals has been adjusted slightly higher to reflect a $1 increase in fair value to $188, lower modeled revenue growth at 2.92%, a higher profit margin assumption at 21.90%, and a reduced future P/E of 13.95, as analysts point to a resilient central nervous system franchise, updated views on Ziihera and zanidatamab opportunities, and recent Q4 results and guidance. Analyst Commentary Recent research coverage points to generally constructive sentiment on Jazz Pharmaceuticals, with a cluster of higher price targets anchored to the company’s central nervous system portfolio and oncology pipeline, including Ziihera and zanidatamab.
ナラティブ更新 • Mar 02

JAZZ: Oncology Readouts And CNS Durability Will Drive Future Upside Potential

Our analyst fair value estimate for Jazz Pharmaceuticals has moved from $230.00 to about $263.59, as analysts factor in stronger margin expectations, a slightly higher discount rate, and ongoing Street enthusiasm around Ziihera and the broader oncology pipeline following recent Q4 updates and HERIZON-GEA data presentations. Analyst Commentary Recent Street research has leaned constructive on Jazz Pharmaceuticals, with multiple bullish analysts revisiting their models following Q4 results and the latest HERIZON-GEA data.
ナラティブ更新 • Feb 16

JAZZ: HER2 Practice-Changing GEA Data Will Drive Future Oncology Leadership

Narrative Update Overview The analyst price target for Jazz Pharmaceuticals has moved higher, with our fair value estimate rising from $213 to $219.40 as analysts factor in stronger Ziihera and zanidatamab potential, supported by recent HERIZON-GEA data and updated Street research. Analyst Commentary Recent Street research on Jazz Pharmaceuticals has been largely constructive, with multiple firms updating their work after the detailed HERIZON-GEA-01 readout and related discussions around Ziihera and zanidatamab.
ナラティブ更新 • Feb 02

JAZZ: Practice-Changing HER2 Data Will Drive Oncology Upside And Rebalance Legacy Risks

Analysts have raised their price targets on Jazz Pharmaceuticals by approximately $10 to $30 per share, citing what they describe as practice-changing HERIZON GEA data for Ziihera and a clearer oncology pipeline driver as key supports for the higher valuations. Analyst Commentary Across recent research notes, analysts have been revising their views on Jazz Pharmaceuticals primarily around the HERIZON GEA data for Ziihera and what it could mean for the oncology portfolio.
ナラティブ更新 • Jan 19

JAZZ: Practice-Changing HER2 Data Will Rebalance Oncology Potential And Legacy Risks

Jazz Pharmaceuticals' updated analyst price target has edged down by US$1 to US$187 as analysts factor in slightly higher growth and margin assumptions, supported by recent HERIZON-GEA-01 data that they describe as practice changing for Ziihera and potentially supportive of new standard-of-care use across several HER2+ cancer settings. Analyst Commentary Across recent research, most firms are reacting to the HERIZON-GEA-01 data by lifting their Jazz Pharmaceuticals price targets and highlighting Ziihera and zanidatamab as key value drivers.
ナラティブ更新 • Jan 05

JAZZ: Oncology Data Will Reshape Revenue Mix While Legacy Headwinds Persist

We are raising our Jazz Pharmaceuticals fair value estimate to $188 from $147 as analysts boost price targets following positive HERIZON-GEA-01 data for Ziihera, which they see as a potential new standard of care and a multibillion dollar revenue driver. Analyst Commentary Street research following the HERIZON-GEA-01 topline readout has turned broadly constructive on Jazz Pharmaceuticals, with multiple firms lifting price targets and reiterating positive ratings.
ナラティブ更新 • Dec 18

JAZZ: HER2-Positive GEA Breakthrough Will Drive Future Oncology Leadership

Analysts have nudged their fair value estimate for Jazz Pharmaceuticals higher to $213.00 from $208.50, reflecting stronger long term revenue growth expectations and a richer future P/E multiple, supported by increasingly bullish views on Ziihera's potential to become a new standard of care in HER2 positive GEA and a key oncology growth driver. Analyst Commentary Bullish analysts are largely focused on the upside from Ziihera's HERIZON-GEA-01 data, with multiple research shops lifting price targets and embedding higher long term oncology growth into their models.
ナラティブ更新 • Dec 04

JAZZ: HER2-Positive GEA Success Will Drive Future Oncology Leadership And Upside

Our fair value estimate for Jazz Pharmaceuticals has nudged higher to $208.50 from $206.38, reflecting analysts' upward revisions to price targets as they factor in expectations of stronger long term revenue growth and profitability. This is driven by Ziihera's potential as a new standard of care in HER2 positive GEA and broader oncology indications.
ナラティブ更新 • Nov 20

JAZZ: Recent Positive Trial Data Will Drive Future Leadership In HER2-Positive Oncology

Analysts have increased their price target for Jazz Pharmaceuticals from approximately $186 to $206 per share. They cite improved revenue growth projections and recent strong clinical data supporting the potential of Ziihera as a standard-of-care therapy in HER2-positive cancers.
分析記事 • Nov 18

Improved Revenues Required Before Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock's 25% Jump Looks Justified

Despite an already strong run, Jazz Pharmaceuticals plc ( NASDAQ:JAZZ ) shares have been powering on, with a gain of...
ナラティブ更新 • Aug 30

Emerging Therapies And Portfolio Expansion Will Shape Future Markets

Analysts have modestly raised their price targets for Jazz Pharmaceuticals, driven by growing confidence in Modeyso's commercial prospects and expanded market potential, partially offset by persistent challenges in other segments, resulting in a new consensus target of $186.47. Analyst Commentary Bullish analysts are increasingly positive on the commercial potential of Modeyso following its recent approval, citing higher-than-expected pricing, a dedicated launch strategy, and strong patient/prescriber interest.

決済の安定と成長

配当データの取得

安定した配当: JAZZの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: JAZZの配当金が増加しているかどうかを判断するにはデータが不十分です。

配当利回り対市場

Jazz Pharmaceuticals 配当利回り対市場
JAZZ 配当利回りは市場と比べてどうか？
セグメント配当利回り
会社 (JAZZ)n/a
市場下位25% (US)1.4%
市場トップ25% (US)4.1%
業界平均 (Pharmaceuticals)1.9%
アナリスト予想 (JAZZ) (最長3年)0%

注目すべき配当: JAZZは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: JAZZは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。

株主への利益配当

収益カバレッジ: JAZZの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。

株主配当金

キャッシュフローカバレッジ: JAZZが配当金を報告していないため、配当金の持続可能性を計算できません。

高配当企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/09/14 18:27
終値2026/09/11 00:00
収益2026/06/30
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した ご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Jazz Pharmaceuticals plc 19 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。49

アナリスト機関
Brian SkorneyBaird
Joel BeattyBaird
null nullBaird